1
|
Szantroch M, Bala A, Rysz A, Żyłkowski J, Marchel A. Experience of adverse events with cerebral propofol testing in patients with drug resistant epilepsy. Sci Rep 2019; 9:592. [PMID: 30679447 PMCID: PMC6345790 DOI: 10.1038/s41598-018-36031-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Accepted: 11/10/2018] [Indexed: 11/09/2022] Open
Abstract
The aim of this study was to assess the type and frequency of adverse events during the Wada test conducted with propofol as an anaesthetic agent. In total, 122 patients with temporal lobe epilepsy underwent the Wada test with propofol between 2006 and 2016 as part of presurgical evaluation at the Department of Neurosurgery of the Medical University of Warsaw. The Wada test was conducted bilaterally on 118 patients (236 cases). In four cases, due to complications, the test was conducted only unilaterally, which resulted in a total of 240 cases. Those cases were further analysed for the presence of adverse events. In all cases, intracranial circulation angiography (via the transfemoral approach) was performed before memory and language testing. Of the 122 patients, adverse events were observed in 75 patients (61.4%). Serious complications were notably rare and observed only in two patients (1.6%): one patient had a carotid artery dissection, and the other had a pseudoaneurysm at the puncture site. Mild adverse events (e.g., shivers or pain of the eye) were highly common - we observed them in 71 patients (58%), but they were short-term and well-tolerated by the subjects. Two patients (1.6%) had a seizure during the Wada test. Most of the adverse events occurring during the Wada test with propofol were mild and short-lived. Considering a small risk of serious damage to health, this procedure can be perceived as a good method for assessing language and memory in a fraction of the epilepsy surgery candidates.
Collapse
Affiliation(s)
- Marta Szantroch
- Department of Neurosurgery, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland
| | - Aleksandra Bala
- Department of Neurosurgery, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland. .,Faculty of Psychology, University of Warsaw, Poland, Stawki 5/7, 00-183, Warsaw, Poland.
| | - Andrzej Rysz
- Department of Neurosurgery, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland
| | - Jarosław Żyłkowski
- Second Department of Radiology, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland
| | - Andrzej Marchel
- Department of Neurosurgery, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland
| |
Collapse
|
2
|
McCleary K, Barrash J, Granner M, Manzel K, Greider A, Jones R. The safety and efficacy of propofol as a replacement for amobarbital in intracarotid Wada testing of presurgical patients with epilepsy. Epilepsy Behav 2018; 78:25-29. [PMID: 29169082 DOI: 10.1016/j.yebeh.2017.10.037] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Revised: 10/25/2017] [Accepted: 10/26/2017] [Indexed: 10/18/2022]
Abstract
OBJECTIVE The intracarotid sodium amytal procedure (the "Wada test") has for many years been the gold standard for language and memory lateralization and remains an important part of presurgical analysis for patients with medically intractable seizures. Due to shortages in the key sedative (amobarbital), neuropsychologists have turned to alternatives such as propofol. Our aim was to investigate the safety and efficacy of propofol relative to amobarbital in the Wada test. METHODS We performed a retrospective review of the 97 Wada procedures performed at University of Iowa Hospitals and Clinics from 2007 through mid-2015. RESULTS Propofol produced similar lateralization rates as amobarbital for both language and memory. Similar rates of patients in each group went on to have the resection surgery. With regard to safety, there were no differences found in average rate or severity of adverse effects. None of the demographic characteristics reviewed were predictive of increased risk for either drug. SIGNIFICANCE These findings support previous studies indicating that propofol is as safe and efficacious as amobarbital, and can continue to be used in Wada procedures with confidence.
Collapse
Affiliation(s)
- Kaci McCleary
- Department of Neurology, University of Iowa, United States.
| | - Joseph Barrash
- Department of Neurology, University of Iowa, United States
| | - Mark Granner
- Department of Neurology, University of Iowa, United States
| | - Kenneth Manzel
- Department of Neurology, University of Iowa, United States
| | - Audrey Greider
- Department of Neurology, University of Iowa, United States
| | - Robert Jones
- Department of Neurology, University of Iowa, United States
| |
Collapse
|
3
|
Bogaarts G, Gommer E, Hilkman D, van Kranen-Mastenbroek V, Reulen J. An improved qEEG index for asymmetry detection during the Wada test. Epilepsy Behav 2016; 62:40-6. [PMID: 27450303 DOI: 10.1016/j.yebeh.2016.06.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2016] [Revised: 06/10/2016] [Accepted: 06/13/2016] [Indexed: 11/30/2022]
Abstract
The Wada test is commonly used to evaluate language and memory lateralization in candidates for epilepsy surgery. The spatial Brain Symmetry Index (BSI) quantifies inter-hemispheric differences in the EEG. Its application has been shown to be feasible during Wada testing. We developed a method for the quantification of EEG asymmetry that matches visual assessments of the EEG better than BSI. Fifty-three patients' EEG data, with a total of 85 injections were analyzed. In a step-wise, data-driven manner, multiple electrode and frequency band combinations were evaluated. Eventually, BSI, calculated using only the frontal electrodes F3 and F4, was combined with a temporal measure of delta power in the central electrodes, C3 and C4, into a new measure: cBSI. Using the area under the ROC curve (AUC), we showed that cBSI performs significantly better relative to BSI (median AUC 0.98 versus 0.96, p=0.0015, Wilcoxon signed rank test). Our results showed that asymmetry detection was significantly improved by combining temporal with spatial qEEG measures. In the future, our combined qEEG measure could allow for a more objective way of monitoring EEG asymmetry, thereby increasing the feasibility of using EEG as a monitoring tool during the Wada test. Future studies should, however, validate our cBSI method in real time in the operating room or radiology suite.
Collapse
Affiliation(s)
- Guy Bogaarts
- Department of Clinical Neurophysiology, AZM Maastricht, Netherlands.
| | - Erik Gommer
- Department of Clinical Neurophysiology, AZM Maastricht, Netherlands
| | - Danny Hilkman
- Department of Clinical Neurophysiology, AZM Maastricht, Netherlands
| | | | - Jos Reulen
- Department of Clinical Neurophysiology, AZM Maastricht, Netherlands
| |
Collapse
|
4
|
Chiu AHY, Bynevelt M, Lawn N, Lee G, Singh TP. Propofol as a substitute for amobarbital in Wada testing. J Clin Neurosci 2015; 22:1830-2. [PMID: 26188665 DOI: 10.1016/j.jocn.2015.04.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2015] [Revised: 04/12/2015] [Accepted: 04/18/2015] [Indexed: 11/16/2022]
Abstract
We describe a patient with equivocal findings on functional MRI (fMRI), who underwent a propofol Wada test, review the literature on this topic and suggest a protocol for the use of propofol for a Wada test. Although fMRI techniques can usually accurately lateralize language, the Wada test remains the gold standard for preoperative lateralization and is occasionally still required if there are non-diagnostic findings on fMRI. Amobarbital, the agent of choice for the Wada test, has become increasingly difficult to obtain and requires regulatory approval, which may delay definitive management and have an impact on patient outcomes. Propofol has been suggested as an alternative to amobarbital, and while there is some published data on this, there is no reported Australian experience to date.
Collapse
Affiliation(s)
- Albert Ho Yuen Chiu
- Neurological Intervention and Imaging Service of Western Australia, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA 6009, Australia; Neurological Intervention and Imaging Service of Western Australia, Royal Perth Hospital, Perth, WA, Australia.
| | - Michael Bynevelt
- Neurological Intervention and Imaging Service of Western Australia, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA 6009, Australia; Neurological Intervention and Imaging Service of Western Australia, Royal Perth Hospital, Perth, WA, Australia
| | - Nicholas Lawn
- Department of Neurology, Royal Perth Hospital, Perth, WA, Australia
| | - Gabriel Lee
- Department of Neurosurgery, Sir Charles Gairdner Hospital, Perth, WA, Australia
| | - Tejinder Pal Singh
- Neurological Intervention and Imaging Service of Western Australia, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA 6009, Australia; Neurological Intervention and Imaging Service of Western Australia, Royal Perth Hospital, Perth, WA, Australia
| |
Collapse
|
5
|
Tu B, Assassi N, Bazil CW, Hamberger MJ, Hirsch LJ. Quantitative EEG is an objective, sensitive, and reliable indicator of transient anesthetic effects during Wada tests. J Clin Neurophysiol 2015; 32:152-8. [PMID: 25580802 PMCID: PMC4385440 DOI: 10.1097/wnp.0000000000000154] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
The intracarotid amobarbital or Wada procedure is a component of the presurgical evaluation for refractory epilepsy, during which monitoring the onset and offset of transient anesthetic effects is critical. In this study, the authors characterized changes of 8 quantitative measures during 26 Wada tests, which included alpha, beta, theta, and delta powers, alpha/delta power ratio, beta/delta power ratio, median amplitude-integrated EEG, and 90% spectral edge frequency (SEF90), and correlated them with contralateral hemiplegia. The authors found that on the side of injection, delta and theta powers, alpha/delta power ratio, beta/delta power ratio, and SEF90 peaked within 1 minute after injection of 70 to 150 mg amobarbital or 4 to 7 mg methohexital. When contralateral arm strength returned to 3/5, delta power and amplitude-integrated EEG decayed on average 24% and 19%, respectively, for amobarbital, similar to that of methohexital (27% and 18%). Because delta power resolution most closely mirrored that of the hemiplegia and amplitude-integrated EEG had the highest signal/noise ratio, these quantitative values appear to be the best measures for decay of anesthetic effects. Increase in alpha power persisted longest, and therefore may be the best measure of late residual anesthetic effects.
Collapse
Affiliation(s)
- Bin Tu
- Columbia University Comprehensive Epilepsy Center, New York, NY 10032
| | - Nadege Assassi
- New York University Pre-Medicine Neural Science Program, New York, NY 10003
| | - Carl W. Bazil
- Columbia University Comprehensive Epilepsy Center, New York, NY 10032
| | | | | |
Collapse
|
6
|
Curot J, Denuelle M, Busigny T, Barragan-Jason G, Kany M, Tall P, Marlat F, Fabre N, Valton L. Bilateral Wada test: Amobarbital or propofol? Seizure 2014; 23:122-8. [DOI: 10.1016/j.seizure.2013.10.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2013] [Revised: 10/18/2013] [Accepted: 10/20/2013] [Indexed: 11/17/2022] Open
|
7
|
González JAJ, Llibre Guerra JC, Prince López JA, Vázquez Luna F, Rodríguez Ramos RM, Ugarte Suárez JC. Feasibility of the superselective test with propofol for determining eloquent brain regions in the endovascular treatment of arteriovenous malformations. Interv Neuroradiol 2013; 19:320-8. [PMID: 24070081 DOI: 10.1177/159101991301900309] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2012] [Accepted: 11/25/2012] [Indexed: 11/17/2022] Open
Abstract
The superselective test for determining eloquent brain areas, carried out prior to the embolization treatment for arteriovenous malformations (AVMs), is a tool contributing to increase the safety of endovascular procedures. Taking into account amobarbital unavailability, it was decided to carry out the present study to demonstrate the efficacy and safety of propofol as an alternative to amobarbital to perform this test. A group of 58 patients were treated in 91 embolization sessions for brain AVMs using endovascular surgery between February 2006 and February 2011. The superselective test was performed prior to embolization with Histoacryl, using the intra-arterial administration of 20 mg propofol through a microcatheter positioned near the AVM nidus. Ten (7.8%) of the 128 superselective tests were positive. Neurological deficits appeared immediately after propofol administration, lasted for one minute and disappeared after five minutes. Only one of the patients showing a negative test result developed neurological deficits after embolization, for 99.2% negative predictive vale. Despite their positive test results, six patients were embolized and five developed post-embolization neurological deficits, for 83.3% positive predictive value. The test showed 83.3% sensitivity and 99.2% specificity. The use of propofol to perform the superselective test during brain AVM embolization is a safe and effective alternative to amobarbital, and may predict the occurrence of post-embolization ischemic complications.
Collapse
Affiliation(s)
- José A Jordán González
- Department of Radiology; Interventional Neuroradiology Unit, Center for Medical-Surgical Investigations (CIMEQ), Medical University of Havana; Havana, Cuba - E-mail:
| | | | | | | | | | | |
Collapse
|
8
|
Magee JA, Pender NP, Abrahams S, Thornton J, Delanty N, Fortune GM. A comparison of propofol and amobarbital for use in the Wada test. Seizure 2012; 21:399-401. [PMID: 22425425 DOI: 10.1016/j.seizure.2012.02.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2011] [Revised: 02/08/2012] [Accepted: 02/09/2012] [Indexed: 12/01/2022] Open
Abstract
129 Wada procedures were reviewed to examine the suitability of propofol (n=54) as a replacement to amobarbital (n=75) for use as an anaesthetic in the Wada test. Suitability was considered with respect to length of hemiplegia induced, the frequency of side effects and patient memory scores. Data was retrospectively collected from records of patients who had undergone the Wada procedure between 2004 and 2009 in Beaumont Hospital, Dublin. No significant differences were found between the two drugs on any of the measures. The results suggest that propofol represents a suitable alternative to amobarbital for use in the Wada procedure.
Collapse
Affiliation(s)
- James A Magee
- Department of Psychology, Beaumont Hospital, Dublin, Ireland
| | | | | | | | | | | |
Collapse
|
9
|
Patel A, Wordell C, Szarlej D. Alternatives to sodium amobarbital in the Wada test. Ann Pharmacother 2011; 45:395-401. [PMID: 21325100 DOI: 10.1345/aph.1p476] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
OBJECTIVE To review the literature and identify alternatives to sodium amobarbital for use in the Wada test. DATA SOURCES A search of PubMed (1960-October 2010) was performed using the following key words alone or in combination: Wada test, intracarotid amobarbital procedure, intracarotid, intraarterial, sodium amobarbital, methohexital, Brevital, pentobarbital, etomidate, propofol, and alternative anesthetics. References of the identified articles were reviewed for relevant information. STUDY SELECTION AND DATA EXTRACTION All articles in English identified from the data sources were evaluated. Review included comparative, prospective, and retrospective studies along with case series and case reports. DATA SYNTHESIS Methohexital, pentobarbital, etomidate, and propofol have all been studied as alternatives to sodium amobarbital in the Wada test. Four controlled experimental trials, 1 uncontrolled experimental trial, 6 retrospective chart reviews, and 2 case reports were reviewed. Methohexital, pentobarbital, and propofol required a second injection due to their short duration of action. Etomidate was studied as a bolus injection followed by a continuous infusion until the critical speech and memory tests were administered, which differed from the standard Wada test procedure. Patients had an increased risk of seizures with methohexital, whereas 1 patient developed transient respiratory depression immediately after receiving pentobarbital. Furthermore, propofol caused increased tone with twitching and rhythmic movements, which interfered with the completion of the Wada test for 1 patient. All authors concluded that these agents were equivalent to amobarbital for the Wada test. CONCLUSIONS Methohexital, pentobarbital, etomidate, and propofol are viable alternatives to sodium amobarbital for use in the Wada test, but each has shortcomings.
Collapse
Affiliation(s)
- Akta Patel
- Thomas Jefferson University Hospital, Department of Pharmacy, Neurosurgery/Critical Care, Philadelphia, PA, USA.
| | | | | |
Collapse
|